Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA
Cancer. 2016 Dec 2;():.
PMID: 27911979 [PubMed - as supplied by publisher]

Routine X-ray of the chest is not justified in staging of cutaneous melanoma patients.
Gjørup CA, Hendel HW, Pilegaard RK, Willert CB, Hölmich LR
Dan Med J. 2016 Dec;63(12):.
PMID: 27910800 [Unknown status]

Metastatic pathways in patients with cutaneous melanoma.
Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ
Pigment Cell Melanoma Res. 2016 Oct 19;():.
PMID: 27900851 [PubMed - as supplied by publisher]

Toll-like receptors and cutaneous melanoma.
Coati I, Miotto S, Zanetti I, Alaibac M
Oncol Lett. 2016 Nov;12(5):3655-3661.
PMID: 27900049 [Unknown status]

Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.
Hübner J, Waldmann A, Geller AC, Weinstock MA, Eisemann N, Noftz M, Bertram S, Nolte S, Volkmer B, Greinert R, Breitbart E, Katalinic A
Br J Cancer. 2016 Nov 29;():.
PMID: 27898656 [PubMed - as supplied by publisher]


NCBI's Disclaimer and Copyright notice